Picture of Taro Pharmaceutical Industries logo

TARO — Taro Pharmaceutical Industries News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedMid Cap

Japan vaccine supplies to be limited, delaying shots for elderly - minister

TOKYO, Feb 22 (Reuters) - Japan will only receive limited
doses of COVID-19 vaccines for the first months of the
inoculation rollout and shots for the elderly will be
distributed gradually, the country's inoculation chief said.
    Pfizer Inc  PFE.N , the maker of Japan's only approved
COVID-19 vaccine, is ramping up production in Europe, but those
increased supplies are not likely to reach Japan until May,
Administrative Reform Minister Taro Kono cautioned on Sunday in
an interview with national broadcaster NHK.
    "We would like to start vaccinations for the elderly in
April, but unfortunately the number of doses allocated to them
will be very limited at first, so we want to start slowly," Kono
said.
    Japan has negotiated to receive more than 500 million doses
of COVID-19 vaccines developed by Western drugmakers. But
domestic regulators have only approved one vaccine so far, and
the nation remains dependent on imported supplies that have been
held up by production snags and export controls.  urn:newsml:reuters.com:*:nL1N2K807E
    Since Kono, the minister for administrative reform, was
tapped last month to lead Japan's vaccination push, he has
resisted giving firm timelines for when doses will arrive and be
distributed. Even so, the government has stuck to a pledge to
secure enough shots for the whole population of 126 million by
June.  urn:newsml:reuters.com:*:nL1N2JV0BG  urn:newsml:reuters.com:*:nL4N2KN05E
    Japan has negotiated to receive 144 million doses of
Pfizer's vaccine this year, and its second shipment of about
450,000 shots arrived on Sunday. 
    The inoculation campaign kicked off last week with doctors
and nurses getting the first shots. The government is
prioritising vaccinations for around 4.7 million medical
workers, about 1 million more than initially estimated.
 urn:newsml:reuters.com:*:nL1N2KP0B4  urn:newsml:reuters.com:*:nL4N2KN05E 

 

 (Reporting by Yoshifumi Takemoto and Rocky Swift; Editing by
Stephen Coates)
 ((yoshifumi.takemoto@thomsonreuters.com))

Recent news on Taro Pharmaceutical Industries

See all news